Our sister site for the surgical ICU: 42 bedside tools for scoring, resuscitation, ventilation, sepsis, trauma, and delirium — same step-by-step format, built for the ICU rotation.
The Vascular Minute · Issue 04 · November 19, 2026 · 5-minute read
CREST: endarterectomy vs stent — and what “equivalent” really meant.
Welcome to Issue No. 4 of The Vascular Minute — vascular surgery pearls, landmark trials, and cases, every two weeks. Plus: a second stent platform for TCAR, a bioengineered vessel at VEITH, and a labeled bridging stent for complex aortic repair.
04Issue19Nov 2026
Free, every two weeks. Get the next issue by email while every edition remains readable here.
Deaths, strokes, MIs or stent thromboses at 30 days in CGUARDIANS II. On November 12, the FDA approved InspireMD’s PMA supplement for the CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) — an 80-cm delivery system, used with an embolic protection system specified in the labeling.
The approval opens access to more than 35,000 TCAR procedures a year in the U.S., and makes InspireMD the first company with both transfemoral CAS and TCAR delivery options for its stent. The approval rests on CGUARDIANS II, a prospective, multicenter, single-arm U.S. study of 50 patients at 11 sites, using the CGuard Prime system with the FDA-cleared Enroute transcarotid neuroprotection system in a high-surgical-risk population: 100% acute device success, no deaths, strokes, myocardial infarctions, or stent thrombosis at 30 days, and complete stent patency in evaluable patients.
Caveat: 50 patients, single-arm, 30 days — encouraging, not definitive. The company’s own SwitchGuard neuroprotection system is still investigational and enrolling in CGUARDIANS III.
Tissue engineering: the bioengineered vessel takes VEITH
52
Patients, some implanted more than 5 years, in the long-term ATEV analysis. Humacyte’s acellular tissue engineered vessel (ATEV) is featured in five presentations at VEITH 2026 this week (November 17–21, New York Hilton Midtown): four Associate Faculty abstracts on Wednesday, November 18 — vascular reconstruction in an infected field, interim Phase 3 results of ATEV vs arteriovenous fistula for hemodialysis access in women, integrated durability and safety across three Phase 3 dialysis-access trials, and long-term explant histology — plus a podium presentation Thursday, November 19, on Symvess in military and civilian trauma.
Days before the meeting, on November 16, Humacyte reported long-term data presented at the ISVTE-ISACB Joint Meeting in Miami: analysis of ATEV tissue from 52 patients across five clinical trials found minimal lipid buildup and no evidence of vulnerable plaques — the first long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel. A supplemental BLA for AV access in hemodialysis is slated for submission this month.
Read the fine print: outside the FDA-approved extremity vascular trauma indication (December 2024), the ATEV is investigational — not approved for sale for dialysis access or PAD.
Fenestrations and branches covered by the new indication. On October 8, the FDA approved a PMA supplement expanding the GORE VIABAHN VBX Balloon Expandable Endoprosthesis to use as a bridging stent maintaining visceral artery perfusion in fenestrated and branched endovascular aortic repair — FEVAR with 6–8 mm fenestrations, and BEVAR with 6–8 mm branches at least 10 mm long.
The expansion follows the EMBRACE study, and Gore is presenting the data at VEITH this week.
Why it matters: the VBX was already a workhorse bridging stent in complex aortic repair. A labeled indication turns off-label habit into on-label practice — and gives the choice a regulatory footing.
Caveat: bridging-stent use is limited to aortic endograft systems in which safety and effectiveness have been demonstrated.
A 72-year-old with an 80% stenosis and a complicated heart.
04
Tool spotlight.
Teaching pearl
The trade is stroke for MI — so price the MI first.
The composite hid the trade: CREST’s headline was a tie: 7.2% vs 6.8%. But the periprocedural components moved in opposite directions — stroke 4.1% with stenting vs 2.3% with surgery; myocardial infarction 1.1% vs 2.3%. Nobody gets the average. Every patient gets one side of the trade.
Quantify the cardiac risk before the conversation: a patient with high perioperative cardiac risk tilts toward stenting — that is where surgery’s excess MI lives. A patient with low cardiac risk removes the main reason to avoid the operation. Run the Revised Cardiac Risk Index before the stent-vs-surgery talk, not after it.
Age is the second axis: CREST’s age interaction was real: under 70, stenting looked better; 70 and over, surgery looked better. Age and cardiac risk often pull in opposite directions — that tension is the consultation.
Anatomy is the third: hostile arch, tortuous internal carotid, heavy calcification — favor surgery. Hostile neck, prior radiation, high lesion — favor stenting. The trial gives you the averages; the anatomy gives you the patient.
Landmark trial
CREST in five minutes — endarterectomy vs stent, and what “equivalent” really meant.
The question: symptomatic or asymptomatic carotid stenosis — carotid-artery stenting, or carotid endarterectomy?
The design: the Carotid Revascularization Endarterectomy versus Stenting Trial. 2,502 patients analyzed (2,522 randomized) at 117 centers in the U.S. and Canada, enrolled 2000–2008: symptomatic stenosis ≥50% or asymptomatic stenosis ≥60%, randomized to stenting (with embolic protection) or endarterectomy. Primary composite: periprocedural stroke, myocardial infarction, or death, or any ipsilateral stroke within 4 years. Published in NEJM, July 2010; median follow-up 2.5 years. Ten-year follow-up reported in NEJM, 2016.
7.2% vs 6.8%4-year primary composite, stenting vs surgery (HR 1.11, 95% CI 0.81–1.51, p = 0.51) — no significant difference
4.1% vs 2.3%Periprocedural stroke, stenting vs surgery (p = 0.01) — higher with stenting
Periprocedural MI
1.1% vs 2.3% (p = 0.03) — higher with surgery.
4-year stroke or death
6.4% vs 4.7% (HR 1.50, p = 0.03) — favoring surgery.
Cranial nerve palsy
0.3% vs 4.7% — the one clear win for stenting.
Age interaction (p = 0.02)
Stenting better under 70, surgery better at 70 and over.
At 10 years, the tie held
Primary composite 11.8% vs 9.9% (HR 1.10, p = 0.51); postprocedural ipsilateral stroke 6.9% vs 5.6% (HR 0.99).
Stroke or death at 10 years
11% vs 7.9% (HR 1.37, p = 0.04) — still favoring surgery.
Why it changed practice: CREST made stenting a legitimate alternative instead of an experiment. It ended the argument about which procedure is “better” and replaced it with individualized choice — anatomy, age, cardiac risk, patient preference. It became the backbone of the 2011 multisociety carotid guidelines, and it set up the question CREST never answered: whether either procedure beats modern medical therapy alone for asymptomatic disease — now CREST-2’s job.
Case + toolkit
Seventy-two, asymptomatic, and a heart that complicates everything.
A 72-year-old man is found to have an 80% right internal carotid artery stenosis on a screening duplex after a bruit is heard at a routine visit. He has never had a TIA or stroke. His history: myocardial infarction two years ago, ejection fraction 45%, diabetes. Revised Cardiac Risk Index: 3 — high risk.
01
Confirm the number. Duplex alone doesn’t decide. Get a CTA and measure the stenosis by the NASCET method — CREST’s thresholds only mean something when the measurement matches the trial’s.
02
Start best medical therapy now, whatever the plan. Antiplatelet, high-intensity statin, blood-pressure and diabetes control, smoking cessation. Medical therapy is the floor, not the fallback.
03
Name the trade honestly. At 72, CREST’s age signal favors surgery — but his cardiac risk favors stenting. There is no default answer here; this is the patient the composite was built for.
04
Bring in the third option. TCAR — surgical access with flow reversal — now has a second approved stent platform (see this week’s news). It belongs in the conversation.
05
Let his values decide. A stroke risk against an MI risk is a preference as much as a calculation. Document the shared decision.
Sources
InspireMD, Inc. FDA approval of PMA supplement for CGuard Prime TransCarotid Stent System for TCAR, November 12, 2026 (CGUARDIANS II, 50 patients). citoday.com
Humacyte, Inc. Acellular tissue engineered vessel featured in five presentations at VEITH 2026, November 11, 2026; long-term atherosclerosis-susceptibility data, November 16, 2026 (52 patients, five trials). capital.com
U.S. Food and Drug Administration. PMA supplement approval letter, GORE VIABAHN VBX Balloon Expandable Endoprosthesis, expanded indication as bridging stent in FEVAR/BEVAR, October 8, 2026 (P160021/S051). accessdata.fda.gov (PDF)
Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11-23.
Brott TG, Howard G, Roubin GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med. 2016;374:1021-1031.
Educational use only. This newsletter is not medical advice and does not replace patient-specific assessment, multidisciplinary judgment, or local protocols. Correlate clinically.
ArchivePast issues
Past issueIssue 03 · November 5, 2026
The Vascular Minute · Issue 03 · November 5, 2026 · 5-minute read
NASCET: the trial that drew the line at 70%.
Welcome to Issue No. 3 of The Vascular Minute — vascular surgery pearls, landmark trials, and cases, every two weeks. Plus: three-year SIRONA results, two FDA decisions, and a case of twenty minutes of aphasia.
03Issue05Nov 2026
Free, every two weeks. Get the next issue by email while every edition remains readable here.
Freedom from clinically driven target lesion revascularization at 3 years with sirolimus-coated balloon, versus 80.2% with paclitaxel-coated balloon (HR 0.60, 95% CI 0.36–0.97, p=0.01) in 482 patients with femoropopliteal disease — presented at TCT 2026 on November 2 and published in JACC: Cardiovascular Interventions.
Caveat: the trial was powered for 12-month endpoints, so the 3-year finding is exploratory; follow-up continues to 5 years.
Hydrogel embolic, expanded indication
100%
Freedom from major adverse events through 30 days in the HALT study (130 patients, 22 US sites), with 90.0% clinical success. On October 29, the FDA expanded the indication for the Instylla Embrace Hydrogel Embolic System to peripheral arterial bleeds in vessels ≤6 mm.
AI-powered IVUS, cleared
On November 4, the FDA granted 510(k) clearance to the Evident Vascular Guidance System and Evident peripheral imaging catheters for AI-powered intravascular ultrasound during peripheral vascular interventions.
Note: not available for sale in the US or other jurisdictions yet; clearance is a milestone, not a launch.
Teaching pearl
Symptomatic first, percent second.
The first question in symptomatic carotid disease is not the percent — it is whether the stenosis caused the event. Once symptoms are established, the degree of stenosis decides how large the benefit of endarterectomy is.
70–99%Operate — large proven benefit.
50–69%Small benefit — selected patients only.
Under 50%No benefit from endarterectomy — medical therapy.
Landmark trial
NASCET in five minutes — the trial that drew the line at 70%.
The question: in symptomatic carotid stenosis, does carotid endarterectomy plus medical therapy beat medical therapy alone?
The measurement: stenosis was measured by the NASCET method, using the distal normal internal carotid artery as the denominator.
26% vs 9%2-year ipsilateral stroke, medical vs surgical — severe 70–99% stenosis
NNT ≈6Absolute risk reduction 17 points at 2 years
Moderate 50–69%
5-year ipsilateral stroke 22.2% vs 15.7% (ARR 6.5 points, p=0.045) — and no clear benefit for women in this band.
Under 50%
No benefit from endarterectomy.
Major or fatal stroke
Absolute reduction of 10.6 points at 2 years in severe stenosis.
Case + toolkit
Twenty minutes of aphasia.
A 68-year-old man has 20 minutes of word-finding difficulty and right-hand clumsiness that fully resolves. Imaging shows 82% symptomatic left internal carotid artery stenosis by the NASCET method.
01
Call it symptomatic and admit — with a stroke workup.
02
Start best medical therapy now — antiplatelet, high-intensity statin, blood-pressure and diabetes control.
03
Plan timely endarterectomy — ideally within 2 weeks if neurologically stable, after confirming the team’s perioperative stroke/death rate is under 6%.
04
Remember the group. 82% symptomatic stenosis is the large-benefit group (NNT ≈6).
Sources
SIRONA / Concept Medical. Three-year results presented at TCT 2026, November 2, 2026; published in JACC: Cardiovascular Interventions.
Instylla FDA expanded indication, October 29, 2026 (HALT study).
Evident Vascular FDA 510(k) clearance, November 4, 2026.
North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–453.
Barnett HJM, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339:1415–1425.
Educational use only. This newsletter is not medical advice and does not replace patient-specific assessment, current device instructions for use, multidisciplinary judgment, or local protocols. Correlate clinically.
Past issueIssue 02 · October 22, 2026
The Vascular Minute · Issue 02 · October 22, 2026 · 5-minute read
Ruptured AAA: resuscitate and decide in parallel.
Welcome to Issue No. 2 of The Vascular Minute — vascular surgery pearls, landmark trials, and cases, every two weeks. Plus: an FDA nod for large-bore closure, SPIRARE II's PE results, and one-year data for no-option CLTI.
02Issue22Oct 2026
Free, every two weeks. Get the next issue by email while every edition remains readable here.
Major complications (VARC-3) in the ELITE arterial study. On October 20, Haemonetics announced FDA approval of PerQseal Elite, a sutureless, fully bioabsorbable patch that seals arteriotomies up to 26 F from inside the vessel after 14–22 F sheath procedures — mean time to hemostasis under a minute, nothing permanent left behind.
Watch next: independent clinical data at TCT 2026 (Oct 31–Nov 3).
PE thrombectomy, published
100%
Technical success in SPIRARE II. Jupiter Endovascular's Vertex system met all primary and secondary endpoints, published October 20 in EuroIntervention: 39% mean RV/LV reduction (p<0.0001), 50% normalized PA pressure, and dyspnea improvements sustained through 30 days — in a sick cohort, 85% intermediate-high risk.
Watch next: positioning versus existing PE devices in real-world use.
No-option CLTI, one year out
84.1%
Limb salvage at one year in PROMISE III, reported at VIVA 2026: LimFlow's transcatheter arterialization of the deep veins (TADV) in 100 no-option CLTI patients, all Rutherford 5/6 — 91.4% survival, 76.3% amputation-free survival, and median pain falling from 6 to 0 at one year.
Caveat: single-arm, no comparator.
Teaching pearl
A ruptured AAA is a clinical diagnosis. Treat it like one.
Permissive hypotension — systolic blood pressure around 80–90 mmHg — until proximal control, not normalization. An unstable patient with a suspected rupture goes to the OR or endovascular suite; do not let the scanner delay hemorrhage control. A patient who is stable enough gets a fast CTA to answer EVAR suitability — that was IMPROVE's whole point.
Landmark trial
No winner at 30 days. The recovery decided it.
The question: in ruptured AAA, an endovascular-first strategy or straight to open repair?
The design: IMPROVE randomized 613 patients across 30 UK centres and one Canadian centre (2009–2013), before the anatomy was known — 316 to an EVAR-first strategy, 297 to open repair.
35.4%EVAR-first 30-day mortality
37.4%Open repair 30-day mortality (p = 0.62 — a draw)
Discharged home
94% of the endovascular-strategy group went directly home within 30 days versus 77% after open repair (p<0.001) — at no extra cost.
Three years
A borderline survival edge for the endovascular strategy: 48% versus 56% had died (p = 0.053).
A signal in women
30-day mortality of 37% with EVAR versus 57% with open repair (interaction p = 0.02).
Case + toolkit
The back pain that didn't wait.
A 71-year-old man with a known 5.9 cm AAA develops sudden tearing back pain to the flank. He is pale and diaphoretic, BP 78/52, heart rate 118.
01
Call it a rupture until proven otherwise. Permissive hypotension, large-bore access, type & cross — activate vascular and endovascular now.
02
Resuscitate in parallel — with blood, not crystalloid.
03
Image only if he lets you. Fast CTA if stable enough to answer EVAR suitability; straight to the OR if not.
04
EVAR-first when anatomy allows — IMPROVE's lesson. Open when it doesn't.
Sources
IMPROVE Trial Investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial. BMJ. 2014;348:f7661.
IMPROVE Trial Investigators. Comparative clinical effectiveness and cost effectiveness of endovascular strategy versus open repair for ruptured abdominal aortic aneurysm: three-year results of the IMPROVE randomised trial. BMJ. 2017.
Educational use only. This newsletter is not medical advice and does not replace patient-specific assessment, current device instructions for use, multidisciplinary judgment, or local protocols. Correlate clinically.
Past issueIssue 01 · October 2026
The Vascular Minute · Issue 01
New in the vascular world.
Three October developments, one practical AAA screening pearl, EVAR-1 in five minutes, and a case that turns evidence into action.
01IssueOct2026
Free, every two weeks. Get the next issue by email while every edition remains readable here.
12-month primary patency. At VIVA 2026, Cordis reported this result with its investigational sirolimus drug-eluting balloon in SELUTION4SFA, a 300-patient randomized U.S. pivotal trial in superficial femoral and proximal popliteal disease.
Why it matters: the result supports an FDA submission, but the device remains investigational in the U.S.
New U.S. venous device clearance
VCD Medical announced FDA 510(k) clearance for VEnice, a nonthermal mechanical closure device for superficial and perforator veins. The system deploys implantable clips under ultrasound guidance through a 17-gauge applicator.
Watch next: independent clinical data and real-world durability.
Aortoiliac innovation enters a pivotal study
Gore announced first enrollment in the investigational EXCLUDER IBE Plus pivotal study for aortoiliac and common iliac aneurysms. The nonrandomized study is planned across about 30 U.S. sites with five-year follow-up.
Watch next: anatomic suitability and internal iliac preservation.
Teaching pearl
Screening finds the aneurysm. Surveillance manages the risk.
A one-time ultrasound is the front door, not the entire pathway. The U.S. Preventive Services Task Force recommends one-time ultrasonography for men aged 65 to 75 years who have ever smoked. It supports selective screening for men in that age range who have never smoked, based on risk factors and patient preferences.
Once an abdominal aortic aneurysm is identified, the question changes from who should be screened? to how should this aneurysm be followed or treated?
3.0–3.9 cmSVS guidance suggests imaging every three years.
4.0–4.9 cmYearly surveillance.
5.0–5.4 cmSurveillance every six months while repair suitability and patient factors are assessed.
Landmark trial
EVAR won the first 30 days. Durability decided the rest of the story.
The question: in patients with large intact AAA who were fit and anatomically suitable for either strategy, how did endovascular aneurysm repair compare with open repair?
The design: EVAR-1 randomized 1,252 patients with AAA of at least 5.5 cm across 37 UK hospitals; 626 were assigned to each group.
1.8%EVAR 30-day operative mortality
4.3%Open repair 30-day operative mortality
0–6 months
Lower aneurysm-related mortality with EVAR in the 15-year analysis.
6 months–8 years
The early survival advantage narrowed; overall results required longer follow-up.
Beyond 8 years
Mortality favored open repair; secondary sac rupture drove much of the late aneurysm-related difference.
From evidence to action
A prior EVAR is not a lifetime all-clear.
A 74-year-old man underwent infrarenal EVAR seven years ago. He has had no surveillance imaging for four years and now reports new persistent back discomfort. He is normotensive and has no peritoneal signs.
01
Reassess stability. A change in hemodynamics, pain, examination, or concern for rupture triggers emergency management.
02
Restore aortic imaging. Obtain urgent vascular evaluation and appropriate cross-sectional imaging; tailor contrast and modality to renal function and local protocol.
03
Interrogate the repair. Look for sac expansion, endoleak, migration, loss of seal, limb problems, and other device-related failure.
04
Close the loop. A result without a documented surveillance or intervention plan is an unfinished encounter.
Sources
U.S. Preventive Services Task Force. Screening for Abdominal Aortic Aneurysm: Recommendation Statement. 2019.
Chaikof EL, et al. SVS practice guidelines on the care of patients with an abdominal aortic aneurysm. Journal of Vascular Surgery. 2018;67(1):2–77.e2.
UK EVAR Trial Investigators. Endovascular versus open repair of abdominal aortic aneurysm. New England Journal of Medicine. 2010;362:1863–1871.
Educational use only. This newsletter is not medical advice and does not replace patient-specific assessment, current device instructions for use, multidisciplinary judgment, or local protocols. Correlate clinically.
NEWLandmark trials · five-minute reads
Six studies that changed vascular practice.
The question, design, result, practice impact, and caveat—distilled for rounds, the OR, and exam review.
Carotid Revascularization Endarterectomy versus Stenting Trial
Question
Stenting vs endarterectomy for carotid stenosis?
Design & enrollment
RCT, n=2,502 (symptomatic and asymptomatic).
Headline result
Primary composite 7.2% stenting vs 6.8% endarterectomy, no significant difference (P=0.51); periprocedural stroke higher with stenting (4.1% vs 2.3%), MI higher with surgery (1.1% vs 2.3%); age interaction—stenting better under 70, surgery better over 70.
Why it changed practice
Legitimized stenting as an alternative; age became the key selection criterion.
One caveat
Composite masks the stroke-vs-MI trade-off; rigorously credentialed operators.
Primary citation NEJM 2010;363:11-23.
Trial 05 · Limb salvage
BEST-CLI
2022
Best Endovascular versus Best Surgical Therapy in CLTI
Question
Bypass vs endovascular for chronic limb-threatening ischemia?
Design & enrollment
Pragmatic RCT, n=1,830 (cohort 1 with adequate saphenous vein n=1,434).
Headline result
Cohort 1 primary composite (major adverse limb event or death) 42.6% surgical vs 57.4% endovascular (HR 0.68, P<0.001); death rates identical between arms.
Why it changed practice
Restored bypass as preferred first-line when adequate vein is available.
One caveat
Benefit driven by fewer reinterventions, not mortality; endovascular techniques have evolved since enrollment.
Primary citation NEJM 2022 (Farber et al.).
Trial 06 · PAD therapy
VOYAGER PAD
2020
Rivaroxaban 2.5 mg twice daily + aspirin vs aspirin alone after lower-extremity revascularization
Question
Does “vascular dose” rivaroxaban improve outcomes post-revascularization?
Design & enrollment
Double-blind RCT, n=6,564.
Headline result
Primary composite (acute limb ischemia, major amputation, MI, ischemic stroke, CV death) 17.3% vs 19.9% (HR 0.85, P=0.009); TIMI major bleeding 2.65% vs 1.87% (P=0.07, not significant).
Why it changed practice
Made low-dose rivaroxaban + aspirin a guideline-supported strategy post-revascularization.
One caveat
Modest absolute benefit (2.6% ARR) vs a real bleeding signal; high-bleeding-risk patients were excluded.
Primary citation NEJM 2020 (Bonaca et al.).
Perioperative cardiac risk
Calculate the Revised Cardiac Risk Index (RCRI), then place it in the context of surgical urgency, active cardiac instability, and functional capacity.
01
Emergency surgery should not be delayed for routine testing that will not change immediate management.
02
Examples include acute coronary syndrome, decompensated heart failure, unstable arrhythmia, or severe symptomatic valvular disease.
03
Intraperitoneal, intrathoracic, or suprainguinal vascular surgery. Infrainguinal and endovascular procedures are not automatically counted by this original definition.
04
05
06
07
08
Equivalent to greater than 176.8 µmol/L.
09
Functional capacity is not part of the RCRI score, but it changes the next step in a perioperative evaluation.
Pseudoaneurysm repair triage
Select the location and high-risk findings. The result separates emergency repair, prompt treatment, and the narrow group of access-site lesions that may be observed.
01
02
cm
The 2 cm observation threshold applies only to uncomplicated post-catheterization femoral pseudoaneurysm.
03
04
Examples: fever, cellulitis, drainage, gas, bacteremia, or perigraft inflammatory change.
05
06
For femoral access lesions, ongoing anticoagulation lowers the chance of spontaneous thrombosis and favors intervention.
Location guide
Femoral accessObserve only when stable, asymptomatic, <2 cm, and off anticoagulation; otherwise treat.
Visceral / renalTreat pseudoaneurysms promptly regardless of diameter because rupture risk is not size-dependent.
Aortic / anastomoticNeeds aortic or vascular-team repair planning; infection and rupture demand urgent source control.
Cervical / traumaticSymptoms, progression, hemorrhage, embolic events, or threatened perfusion favor open or endovascular repair.
Dialysis accessRepair for growth, infection, pain, skin thinning/erosion, bleeding, thrombosis, or access dysfunction.
Any locationActive bleeding, shock, ischemia, infection, skin loss, or neurologic compression overrides size.
Rutherford chronic ischemia
Choose the most advanced symptom or tissue-loss finding. The result gives the chronic lower-extremity ischemia category and its clinical meaning.
01
Endoleak pattern
Identify the source of sac flow, then refine the subtype when applicable.
01
02
SVS WIfI stage
Grade wound, derive ischemia from pressure data, and grade infection. The official 64-cell matrix returns stage 1–4 and estimated 1-year amputation risk.
01
02
ABI
toe mmHg
Toe pressure is used preferentially when entered; especially useful when ABI is noncompressible.
03
Rutherford acute limb ischemia
Answer each bedside question. The result combines neurologic findings and Doppler signals to estimate limb viability.
01
02
03
04
05
06
07
This distinguishes irreversible-grade sensory loss from paresthesia or limited sensory change.
08
Grade III requires profound motor loss or rigor, not venous silence alone.
09
10
Aneurysms
Start with the exact location or screening pathway. Only the relevant questions appear, so every aneurysm type stays easy to find.
Find the right pathway
Choose screening or an aneurysm location.
AAA screening — USPSTF
Enter age, sex, smoking exposure, and family history to generate the USPSTF one-time screening recommendation.
01
02
03
04
Popliteal artery aneurysm
Enter the largest diameter. Symptoms override the routine elective size threshold.
01
02
cm
03
03
Carotid intervention
Combine recent ipsilateral symptoms with NASCET stenosis. The result frames evidence-based candidacy, not procedural choice.
01
02
%
03
Traditional thresholds: <6% perioperative stroke/death for symptomatic disease; <3% for asymptomatic disease.
Chronic mesenteric ischemia
Combine the classic symptom pattern with anatomic disease. Diagnosis requires compatible symptoms and significant mesenteric occlusive disease—not imaging alone.
01
CMI should also remain in the differential for unexplained weight loss, diarrhea, nausea, or exercise-induced abdominal pain after other causes are assessed.
02
CTA is the preferred definitive study; fasting duplex is an appropriate screening test when performed in a validated vascular laboratory.
03
An acute change overrides the elective chronic pathway.
High-yield guide
Typical presentationPostprandial pain, food fear, and weight loss are classic, but the full triad is not required.
Confirm anatomyCTA defines stenosis, occlusion, collaterals, and treatment anatomy; duplex is a screening examination.
SMA is primaryThe SMA is the preferred revascularization target; endovascular treatment is generally first-line when anatomy is suitable.
Single-vessel diseaseIsolated celiac disease requires careful clinical correlation and evaluation for alternative diagnoses.
Asymptomatic diseaseDo not revascularize an incidental single-vessel stenosis routinely; manage atherosclerotic risk and follow selectively.
Acute changeContinuous pain, peritonitis, or instability requires the acute mesenteric ischemia pathway.
CEAP classification
Build the full clinical, etiologic, anatomic, and pathophysiologic descriptor.
01
02
03
04
If none are selected, the calculator reports An.
05
Aortoiliac TASC II
Select the closest lesion pattern. The result returns an anatomic grade and the original TASC treatment direction.
01
CIA = common iliac; EIA = external iliac; CFA = common femoral.
Aortic dissection
Locate the dissection and flag complications to classify Stanford/DeBakey type and management urgency.
01
02
03
IVC filter indications
Identify when temporary mechanical pulmonary-embolism protection may add benefit—and when anticoagulation remains the preferred treatment.
01
02
03
Consider thrombus burden, cardiopulmonary reserve, expected duration without anticoagulation, and whether the acute VTE can embolize.
High-yield guide
Classic indicationAcute proximal DVT or PE with an absolute or temporary contraindication to therapeutic anticoagulation.
Do not add routinelyWhen acute VTE is being treated successfully with therapeutic anticoagulation, routine filter placement is discouraged.
Anticoagulation “failure”Confirm recurrence, adherence, dose, interactions, and the underlying cause rather than automatically adding a filter.
Primary prophylaxisRoutine filters are not recommended for trauma, major surgery, or immobility without documented acute VTE.
Plan retrieval at placementUse structured follow-up; remove a retrievable filter once PE risk is mitigated unless removal risk outweighs benefit.
Resume anticoagulationStart or restart therapeutic anticoagulation as soon as bleeding risk and the clinical situation safely allow.
Acute mesenteric ischemia
Rapidly triage suspected AMI by mechanism, physiology, and peritoneal findings. A normal lactate does not exclude early ischemia.
01
CTA should be obtained without delay when AMI is suspected; do not wait for lactate elevation.
02
Peritoneal signs imply bowel necrosis until proven otherwise and require immediate operative evaluation.
03
04
Anticoagulation is commonly started early, but active bleeding and operative context require individualized judgment.
Do not miss
DiagnosisObtain biphasic CTA without delay. Oral contrast is not indicated and can obscure evaluation.
ResuscitationCorrect volume and electrolyte deficits, begin broad-spectrum antibiotics, decompress the stomach, and trend perfusion.
Arterial AMIRestore SMA flow urgently; an endovascular-first approach is reasonable when expertise is available and no laparotomy indication exists.
Venous AMITherapeutic unfractionated heparin is first-line when there is no peritonitis or bowel necrosis.
NOMIReverse the precipitating low-flow state, minimize vasoconstrictors when feasible, and consider catheter-directed vasodilator therapy.
PeritonitisProceed to emergency exploration, resect nonviable bowel, restore flow when indicated, and plan second-look assessment when viability is uncertain.
Mesenteric duplex
Interpret a fasting native-vessel PSV using either traditional or AbuRahma validation thresholds.
01
02
cm/s
03
Renal artery stenosis
Combine renal duplex criteria with the clinical syndrome to separate medical management from selective revascularization evaluation.
01
Revascularization benefit is selective; anatomy alone is not an indication.
02
cm/s
cm/s
Enter aortic PSV to calculate the renal-aortic ratio; complete waveform and anatomic review still matters.
03
04
Intervention guide
Medical therapy firstMost stable atherosclerotic renal artery stenosis is treated with blood-pressure, lipid, antiplatelet, diabetes, and smoking-risk management.
Cardiac destabilizationRecurrent flash pulmonary edema or recurrent heart-failure syndromes are high-value reasons for specialist revascularization review.
Resistant hypertensionConfirm adherence, out-of-office pressure, and medication optimization before attributing uncontrolled pressure to the lesion.
Renal declineProgressive dysfunction is most concerning with bilateral high-grade disease or stenosis to a solitary functioning kidney.
Duplex contextPSV ≥180 cm/s with supportive findings or renal-aortic ratio ≥3.5 supports ≥60% stenosis; use laboratory-validated criteria.
Do not treat imaging aloneRevascularization should follow a compatible clinical syndrome, hemodynamically important disease, viable renal parenchyma, and multidisciplinary review.
Dialysis access selection & maturation
Choose fistula versus graft using the patient’s ESKD Life-Plan, then check the expected timeline and bedside warning signs for a newly created access.
01
02
03
Site choice should also preserve future options and match anticipated dialysis duration, comorbidity, and prior access history.
02
mL/min
mm
mm
weeks
The Rule of 6s is a supportive bedside heuristic, not an absolute substitute for successful two-needle cannulation.
02
weeks
Standard grafts are generally not cannulated for at least 2 weeks and not until postoperative swelling has subsided. Early-cannulation graft timing is device-specific.
03
04
05
Fistula versus graft
AV fistulaBest when suitable vessels and time permit: fewer infections and interventions after maturation, but slower and less predictable usability.
AV graftUseful when veins are unsuitable or access is needed sooner; cannulates earlier and has more predictable anatomy, but more infection and thrombosis.
Fistula expectationReview the wound early and evaluate maturation at 4–6 weeks. Some fistulas need several months or a salvage procedure before reliable use.
Standard graft expectationUsually wait at least 2 weeks and until swelling subsides enough to palpate the graft course.
Early-cannulation graftMay be usable sooner, but only according to the specific device instructions and local access-team protocol.
Patient firstKDOQI favors an individualized ESKD Life-Plan—not a universal “fistula first” rule—while preserving future access sites.
Vascular surveillance
Interpret bypass, EVAR, native carotid, post-endarterectomy, or post-stent findings and identify the next surveillance or referral step.
01
02
EDV cm/s
02
02
%
03
04
Includes reasonable life expectancy and acceptable procedural risk after specialist review.
05
Examples require full-study interpretation and may include progression, silent infarction, microemboli, plaque ulceration, or impaired cerebrovascular reserve.
02
PSV cm/s
EDV cm/s
03
04
05
mo since procedure
mo since duplex
06
07
Includes progressive restenosis, abnormal baseline study, contralateral disease, or patient factors such as diabetes, chronic kidney disease, smoking, or female sex.
Two-level Wells DVT score
Answer yes or no for each criterion. The score estimates pretest probability and must be followed by the validated diagnostic pathway.
01
02
03
04
05
06
07
08
09
10
Acute compartment syndrome
Combine the bedside examination with absolute and delta pressure. A clinically clear case should not wait for pressure confirmation.
01
02
03
04
mm Hg
mm Hg
Hard vs soft signs of vascular trauma
Screen an extremity injury for findings that direct immediate exploration versus vascular imaging.
Hard signs
01
02
03
04
Soft signs and screening index
05
06
07
08
Leave blank if the limb is too unstable or the measurement is not reliable.
Heparin and protamine dosing
Calculate an example intraoperative unfractionated-heparin bolus and a time-adjusted protamine range.
01
kg
02
100 units/kg IV
The cited open-AAA study protocol measures ACT after 5 minutes and then every 30 minutes; use the dose, ceiling, exclusions, and ACT target validated by the operative team.
03
units
Leave blank to use the calculated bolus. Enter the actual cumulative dose when redosing occurred.
04
minutes
The estimate applies the prescribing information’s approximate 30-minute IV heparin half-life.
Catheter-directed thrombolysis contraindications
Screen acute limb ischemia for absolute and relative contraindications before considering catheter-directed thrombolysis.
01
02
03
04
05
06
07
08
09
10
11
Vascular graft infection
Separate a superficial surgical-site infection from prosthetic involvement, then identify anastomotic disruption, bleeding, bacteremia, and sepsis that mandate urgent source control.
01
02
03
04
05
Classification and workup
Szilagyi ICellulitis involving the wound without deeper tissue or graft involvement.
Szilagyi IISubcutaneous infection without direct contact with the prosthesis.
Szilagyi IIIInfection reaches or involves the vascular prosthesis.
Samson 3–5Progresses from graft-body involvement to anastomotic involvement, bleeding, or bacteremia.
DiagnosisObtain blood cultures and deep operative or image-guided samples; superficial swabs alone are inadequate.
ImagingCTA is first-line; FDG-PET/CT or labeled-leukocyte imaging can clarify equivocal cases.
Varicose vein treatment selection
Combine symptoms, CEAP class, reflux anatomy, peak reflux velocity, vein diameter, and prior treatment to frame the next treatment option.
01
02
03
04
cm/s
Adjunctive evidence only. Pathologic reflux is defined by reversed-flow duration and anatomy; no validated velocity cutoff selects stripping over ablation.
05
mm
Diameter is documented, but current guidance advises against using truncal diameter alone to decide whether symptomatic C2 disease warrants ablation.
06
About us
Where surgery meets innovation.
Joe Braham Joseph Chahine is a surgical resident with a particular interest in vascular surgery and innovation. He is the founder and manager of JRCHealthTech, LLC, a company focused on making life better for surgeons and patients.
Privacy Policy
How this free educational reference handles information.
Free educational reference
This site is a free educational reference for vascular surgery trainees. Its calculators provide educational estimations only and do not replace clinical judgment.
No account or personal details
No account is needed. The site does not ask for or store names, email addresses, or contact details.
Calculator inputs stay in your browser
Inputs are entered by the visitor and processed locally in the browser. Calculator selections and patient-specific inputs are not transmitted to or stored by the site owner.
Google Analytics
This site uses Google Analytics to understand overall traffic and improve the educational reference. Google may collect usage and technical information such as pages viewed, referring source, browser or device characteristics, approximate location, and an IP address, and may use cookies or similar technologies. Calculator selections and patient-specific inputs are not intentionally included in analytics events. Visitors can limit analytics through browser privacy settings or content-blocking tools.
Questions
Visitors with questions can reach the site owner through the information in the About Us section.
References
Clinical criteria and thresholds are keyed from each section to the sources below.
Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. Journal of Vascular Surgery. 1997;26(3):517–538. Clinical classification table and citation.
Society for Vascular Surgery. Endoleaks (Type I–V). Patient and professional reference. SVS.
Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). Journal of Vascular Surgery. 2014;59(1):220–234.e2. doi:10.1016/j.jvs.2013.08.003. Open review with original citation.
Wanhainen A, Van Herzeele I, Bastos Gonçalves F, et al. ESVS 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. European Journal of Vascular and Endovascular Surgery. 2024. Guideline update.
Society for Vascular Surgery. Clinical practice guidelines on popliteal artery aneurysms. Guideline summary.
Chaer RA, Abularrage CJ, Coleman DM, et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. Journal of Vascular Surgery. 2020;72(1S):3S–39S. Full text.
Naylor AR, Rantner B, Ancetti S, et al. ESVS 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery. 2023;65(1):7–111. Guideline PDF.
Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2020;8(3):342–352. Full text.
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery. 2007;33 Suppl 1:S1–S75. doi:10.1016/j.ejvs.2006.09.024. Citation in ACCF/AHA update.
Isselbacher EM, Preventza O, Hamilton Black J III, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146:e334–e482. Full guideline.
Applied Radiology. Chronic mesenteric ischemia: mesenteric artery duplex sonography and the utility of postprandial imaging. 2024. Includes traditional criteria and AbuRahma et al. validation thresholds. Peer-reviewed review.
Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Annals of Internal Medicine. 1995;122:833–838. Criteria summarized in Ultrasound Quarterly review.
Granata A, Fiorini F, Andrulli S, et al. Doppler ultrasound and renal artery stenosis: an overview. Diagnostic review and technical criteria. AORTA review.
Robbin ML, Greene T, Cheung AK, et al. Arteriovenous fistula development in the first 6 weeks after creation. Radiology. 2016;279(2):620–629. KDOQI maturation criteria summarized in the Hemodialysis Fistula Maturation Study. Open full text.
Applied Radiology. US evaluation of arteriovenous fistula complications in the emergency setting. Physical examination and dialysis-access steal findings. Peer-reviewed review.
Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. Journal of Vascular Surgery. 2018;68(1):256–284. Guideline PDF.
Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. Journal of Vascular Surgery. 2018;67(1):2–77.e2. Recommendation summary.
National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE guideline NG158. Updated 2023. Two-level DVT Wells score and pathway. NICE recommendations.
American Association for the Surgery of Trauma. Acute Extremity Compartment Syndrome. Clinical signs and pressure criteria. AAST clinical resource.
US Preventive Services Task Force. Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(22):2211–2218. Recommendation summary.
Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. American Heart Association guideline hub.
De Maeseneer MG, Kakkos SK, Aherne T, et al. ESVS 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. European Journal of Vascular and Endovascular Surgery. 2022;63(2):184–267. ESVS guideline.
Huber TS, Björck M, Chandra A, et al. Chronic mesenteric ischemia: clinical practice guidelines from the Society for Vascular Surgery. Journal of Vascular Surgery. 2021;73(1S):87S–115S. SVS guideline record.
Bhalla V, Textor SC, Beckman JA, et al. Revascularization for Renovascular Disease: A Scientific Statement From the American Heart Association. Hypertension. 2022;79:e128–e143. PubMed record.
Giannakakis S, Galyfos G, Sachmpazidis I, et al. Thrombolysis in peripheral artery disease. Therapeutic Advances in Cardiovascular Disease. 2017;11(4):125–132. Open full text.
Fox N, Rajani RR, Bokhari F, et al. Evaluation and management of penetrating lower extremity arterial trauma: an Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2012;73(5 Suppl 4):S315–S320. EAST guideline.
DailyMed. Heparin Sodium Injection prescribing information: neutralization with protamine sulfate. US prescribing information.
Hiippala ST, et al. Laboratory assessment of unfractionated heparin with activated clotting time and anti-Xa activity during peripheral arterial angiographic procedures. Diagnostics. 2023;13(8):1489. Open full text.
Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2024;12(1):101670. Guideline PDF.
Wiersema AM, et al. ACTION-1: study protocol for ACT-guided heparinization during open abdominal aortic aneurysm repair. Trials. 2021;22:565. Open full text.
Singh K, et al. Peak reflux velocity as an adjunctive duplex marker in lower-limb chronic venous disease. 2020. The study reported 27.4 cm/s as an observational saphenofemoral-junction discriminator, not a treatment-selection threshold. Study record.
Naylor AR, Rantner B, Ancetti S, et al. ESVS 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery. 2023;65(1):7–111. Guideline PDF.
AbuRahma AF, Avgerinos ED, Chang RW, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. Journal of Vascular Surgery. 2022;75(1S):4S–22S. Full text.
Setacci C, Chisci E, Setacci F, Iacoponi F, de Donato G. Grading carotid intrastent restenosis: a 6-year follow-up study. Stroke. 2008;39(4):1189–1196. Prospective velocity study.
Szegedi I, et al. Role of carotid duplex in the assessment of carotid artery restenosis after endarterectomy or stenting. Frontiers in Neurology. 2023;14:1226220. Systematic review.
Krawisz A, Carroll B, Secemsky E. Risk-stratification and management of extracranial carotid artery disease. Cardiology Clinics. 2021. Evidence review summarizing AHA/ASA recommendations for symptomatic carotid stenosis and procedure selection. Open review.
Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100(10):1043–1049. doi:10.1161/01.CIR.100.10.1043. Full text.
Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. Journal of the American College of Cardiology. 2024. Full guideline.
Attachaipanich T, Khawaja M, Takahashi EA, et al. Percutaneous coronary intervention and vascular access complications: a contemporary review. 2026. Post-catheterization pseudoaneurysm observation, thrombin injection, and operative indications. Open full text.
Wahlgren CM, Aylwin C, Davenport RA, et al. ESVS 2025 Clinical Practice Guidelines on the Management of Vascular Trauma. European Journal of Vascular and Endovascular Surgery. 2025;69(2):179–237. Open guideline.
Pseudoaneurysmatic complication of an arteriovenous graft in a hemodialysis patient. F1000Research. 2013;2:228. Dialysis-access pseudoaneurysm complications and operative treatment. Open full text.
Kaufman JA, Barnes GD, Chaer RA, et al. Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease. Journal of Vascular and Interventional Radiology. 2020;31(10):1529–1544. doi:10.1016/j.jvir.2020.06.014. Guideline summary and full-text link.
Bala M, Catena F, Kashuk J, et al. Acute mesenteric ischemia: updated guidelines of the World Society of Emergency Surgery. World Journal of Emergency Surgery. 2022;17:54. doi:10.1186/s13017-022-00443-x. Open guideline.
National Kidney Foundation. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Patient-centered ESKD Life-Plan, AVF maturation review, and AVG cannulation timing. Guideline PDF.
Chakfé N, Diener H, Lejay A, et al. ESVS 2020 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections. European Journal of Vascular and Endovascular Surgery. 2020;59(3):339–384. doi:10.1016/j.ejvs.2019.10.016. Guideline record.
Post-CEA and post-CAS velocities require reconstruction-specific criteria, morphology, interval comparison, and local vascular-laboratory validation. Near-occlusion, contralateral occlusion, low cardiac output, tandem disease, and technical factors may require different interpretation.